Dyne Therapeutics (NASDAQ:DYN – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Profitability
This table compares Dyne Therapeutics and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyne Therapeutics | N/A | -61.46% | -50.94% |
| MediWound | -140.80% | -65.79% | -30.16% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Dyne Therapeutics and MediWound, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyne Therapeutics | 1 | 2 | 11 | 3 | 2.94 |
| MediWound | 1 | 1 | 3 | 0 | 2.40 |
Valuation and Earnings
This table compares Dyne Therapeutics and MediWound”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyne Therapeutics | N/A | N/A | -$446.21 million | ($3.54) | -5.12 |
| MediWound | $16.96 million | 12.17 | -$23.88 million | ($2.10) | -7.67 |
MediWound has higher revenue and earnings than Dyne Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Dyne Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
Summary
Dyne Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.
About Dyne Therapeutics
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
